search button
Open Access

Radium‑223 in patients with metastatic castration‑resistant prostate cancer: Efficacy and safety in clinical practice

  • Authors:
    • Arsela Prelaj
    • Sara Elena Rebuzzi
    • Federica Buzzacchino
    • Chiara Pozzi
    • Carla Ferrara
    • Viviana Frantellizzi
    • Giulia Anna Follacchio
    • Liana Civitelli
    • Giuseppe De Vincentis
    • Silverio Tomao
    • Vincenzo Bianco

  • View Affiliations

  • Published online on: November 30, 2018     https://doi.org/10.3892/ol.2018.9785
  • Pages: 1467-1476

  • Copyright: © Prelaj et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Radium‑223 has improved overall survival (OS) and reduced symptomatic skeletal events (SSE) in patients with metastatic castration‑resistant prostate cancer (mCRPC) and bone metastases (ALSYMPCA trial). Our aim was to assess clinical and biochemical factors related to survival, safety and survival outcomes of Radium‑223 in a clinical practice setting. We retrospectively analysed 32 mCRPC patients treated with Radium‑223, assessing bone scan, pain reduction, alkaline phosphatase (ALP) and prostate‑specific antigen (PSA) response (≥30% reduction). At scintigraphic assessment, 41% had partial response with a disease control rate of 91%; 56% had ALP response and 25% had PSA response; 41% had pain reduction with pain control of 72%. Scintigraphic response and stability were correlated with longer median progression‑free survival (mPFS) (13 and 12 vs. 6 months; P=0.002) and mOS (16 and 12 vs. 6 months; P=0.003). ALP response was associated with longer mPFS (13 vs. 12 months; P=0.2) and mOS (16 vs. 12 months; P=0.2). PSA response was associated with longer mPFS (13 vs. 12 months; P=0.02), whereas mOS could not be computed. Pain response and stability were associated with survival benefit according to mPFS (13 and 12 vs. 9 months) and mOS (both 16 vs. 12 months) without statistical significance. Baseline ALP <220 UI/l, Eastern Cooperative Oncology Group (ECOG) performance status 0 and absence of previous chemotherapy correlated with statistically significantly longer survival outcomes. Skeletal‑related events (SRE) occurred in three patients and median time to first SRE was 9.5 months, mPFS was 12 months and mOS 14 months. G3‑G4 toxicities developed in 16% of patients. Our results are in line with those reported in the pivotal trial and in other retrospective studies. In conclusion, Radium‑223 was associated with high scintigraphic, biochemical and pain response rates and was tolerated well by most patients. Response to Radium‑223 and better baseline factors correlated to longer survival in clinical practice experience as in the clinical trial setting.
View Figures
View References

Related Articles

Journal Cover

February-2019
Volume 17 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Prelaj A, Rebuzzi SE, Buzzacchino F, Pozzi C, Ferrara C, Frantellizzi V, Follacchio GA, Civitelli L, De Vincentis G, Tomao S, Tomao S, et al: Radium‑223 in patients with metastatic castration‑resistant prostate cancer: Efficacy and safety in clinical practice. Oncol Lett 17: 1467-1476, 2019.
APA
Prelaj, A., Rebuzzi, S.E., Buzzacchino, F., Pozzi, C., Ferrara, C., Frantellizzi, V. ... Bianco, V. (2019). Radium‑223 in patients with metastatic castration‑resistant prostate cancer: Efficacy and safety in clinical practice. Oncology Letters, 17, 1467-1476. https://doi.org/10.3892/ol.2018.9785
MLA
Prelaj, A., Rebuzzi, S. E., Buzzacchino, F., Pozzi, C., Ferrara, C., Frantellizzi, V., Follacchio, G. A., Civitelli, L., De Vincentis, G., Tomao, S., Bianco, V."Radium‑223 in patients with metastatic castration‑resistant prostate cancer: Efficacy and safety in clinical practice". Oncology Letters 17.2 (2019): 1467-1476.
Chicago
Prelaj, A., Rebuzzi, S. E., Buzzacchino, F., Pozzi, C., Ferrara, C., Frantellizzi, V., Follacchio, G. A., Civitelli, L., De Vincentis, G., Tomao, S., Bianco, V."Radium‑223 in patients with metastatic castration‑resistant prostate cancer: Efficacy and safety in clinical practice". Oncology Letters 17, no. 2 (2019): 1467-1476. https://doi.org/10.3892/ol.2018.9785